Article
Infectious Diseases
Pattarachai Kiratisin, Marie Kempf, Gregory Stone, Eric Utt
Summary: The objective of this study was to assess the distribution and antimicrobial susceptibility of Pseudomonas aeruginosa isolates against ceftazidime-avibactam (CAZ-AVI) and a panel of comparator agents collected globally and in each region from 2017-2020. The results showed that 20.9% of P. aeruginosa isolates were multidrug resistant (MDR), 20.7% were extremely drug resistant (XDR), 8.4% were CAZ-AVI-resistant (CAZ-AVI-R), and 3.0% were MBL-positive. The highest proportion of resistant isolates was found in Latin America. Rating: 8 out of 10.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Infectious Diseases
Mark G. Wise, James A. Karlowsky, Meredith A. Hackel, Mohamed Amine Harti, Bontle M. E. Ntshole, Eva Njeri Njagua, Rita Oladele, Catherine Samuel, Shameema Khan, Jeannette Wadula, Warren Lowman, Busisani W. Lembede, Daniel F. Sahm
Summary: This study reports the in vitro susceptibility of Enterobacterales and Pseudomonas aeruginosa isolates collected from patients in sub-Saharan Africa to various antimicrobial agents, showing a high susceptibility to ceftazidime-avibactam.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Microbiology
Maria M. Montero, Sandra Domene Ochoa, Carla Lopez-Causape, Sonia Luque, Luisa Sorli, Nuria Campillo, Inmaculada Lopez Montesinos, Eduardo Padilla, Nuria Prim, Ariadna Angulo-Brunet, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: Ceftazidime-avibactam (CZA) has shown promise in treating Pseudomonas aeruginosa infections, particularly those that are extensively drug-resistant (XDR). Combination therapy with CZA and other antibiotics was more effective than monotherapy against XDR isolates, including those resistant to CZA. This study highlights the potential of CZA combinations in treating difficult-to-treat XDR P. aeruginosa infections.
MICROBIOLOGY SPECTRUM
(2021)
Article
Infectious Diseases
D. Pierard, G. G. Stone
Summary: Across all regions, respiratory isolates of Enterobacterales and Pseudomonas aeruginosa showed highest susceptibility rates to ceftazidime-avibactam, colistin, and amikacin. Tigecycline demonstrated activity against all Citrobacter koseri and Escherichia coli subsets, while colistin was active against all subsets of P. aeruginosa.
BMC INFECTIOUS DISEASES
(2021)
Article
Microbiology
Yiwei Zhu, Jie Chen, Han Shen, Zhongju Chen, Qi-Wen Yang, Jin Zhu, Xi Li, Qing Yang, Feng Zhao, Jingshu Ji, Heng Cai, Yue Li, Linghong Zhang, Sebastian Leptihn, Xiaoting Hua, Yunsong Yu
Summary: Klebsiella pneumoniae carbapenemase (KPC)-producing Pseudomonas aeruginosa (KPC-PA) strains were found in 40.4% of carbapenem-resistant P. aeruginosa (CRPA) isolates, with half of them resistant to ceftazidime-avibactam (CAZ-AVI). Eight plasmid types and two mobile genetic elements mediating bla(KPC-2) transmission were identified through sequencing. Curing bla(KPC-2) plasmids in 28 strains restored CAZ-AVI susceptibility, indicating its role in resistance.
Article
Microbiology
Leilei Wang, Xuefei Zhang, Xun Zhou, Fan Yang, Qinglan Guo, Minggui Wang
Summary: The emergence of difficult-to-treat resistance in Pseudomonas aeruginosa is a global challenge. Three beta-lactamase inhibitor combinations (CZA, IMR, and ceftolozane-tazobactam) showed high susceptibility in clinical isolates of P. aeruginosa. CZA exhibited better activity against KPC-2-producing P. aeruginosa and also showed good efficacy against CAZ-NS and IPM-NS isolates.
MICROBIOLOGY SPECTRUM
(2023)
Article
Infectious Diseases
Raul Recio, Jennifer Villa, Sara Gonzalez-Bodi, Patricia Branas, Maria Angeles Orellana, Mikel Mancheno-Losa, Jaime Lora-Tamayo, Fernando Chaves, Esther Viedma
Summary: This study analyzed the phenotypic and genomic characteristics of ceftazidime/avibactam (CZA) resistance in different GES-producing Pseudomonas aeruginosa isolates. The results showed that all CZA-resistant isolates belonged to the ST235 clone and O11 serotype, and different mutations within the bla(GES)(-20) gene were associated with CZA resistance, suggesting the involvement of other resistance mechanisms.
Review
Infectious Diseases
Alessandro Mancuso, Luca Pipito, Raffaella Rubino, Salvatore Antonino Distefano, Donatella Mangione, Antonio Cascio
Summary: BJIs caused by multidrug-resistant gram-negative bacteria are becoming a concern. Ceftazidime-avibactam has shown efficacy and safety in treating osteomyelitis and prosthetic joint infections, despite not being approved for these indications. This study presents three successful cases of resistant Pseudomonas aeruginosa osteomyelitis treated with ceftazidime-avibactam alone or in combination therapy.
Article
Infectious Diseases
Katalin Kristof, Vaclava Adamkova, Amos Adler, Eugenia Gospodarek-Komkowska, Alexandru Rafila, Sabina Billova, Barbara Mozejko-Pastewka, Ferenc Kiss
Summary: The study collected a large number of isolates, finding that Enterobacterales were most susceptible to ceftazidime-avibactam, colistin, and meropenem, while P. aeruginosa showed high susceptibility to colistin. Ceftazidime-avibactam exhibited high susceptibility rates in the ceftazidime-resistant and MDR subsets as well.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
(2021)
Article
Pharmacology & Pharmacy
Maria Jose Contreras-Gomez, Jose R. W. Martinez, Lina Rivas, Roberto Riquelme-Neira, Juan A. Ugalde, Aniela Wozniak, Patricia Garcia, Jose M. Munita, Jorge Olivares-Pacheco, Manuel Alcalde-Rico
Summary: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a pathogen that urgently requires new drugs and control methods. Combining beta-lactam drugs with beta-lactamase inhibitors is the primary strategy against this bacterium. This study found that RND efflux pumps play a role in the susceptibility of CRPA to certain combination antibiotics.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Baharak Babouee Flury, Anja Bosch, Valentin Gisler, Adrian Egli, Salome N. Seiffert, Oliver Nolte, Jacqueline Findlay
Summary: This study aimed to determine the molecular mechanisms of CZA and IPM-resistance in clinical P. aeruginosa isolates obtained from Swiss hospitals. The results demonstrated that CZA-resistance in P. aeruginosa is likely multifactorial and could be caused by the interplay between different resistance mechanisms, including ESBL carriage, increased efflux, loss of permeability, and derepression of its intrinsic ampC.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Infectious Diseases
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
Summary: This study aimed to investigate the susceptibility and β-lactamase-encoding genes of Pseudomonas aeruginosa isolates with discrepant resistance to different carbapenems. Data on P. aeruginosa isolates from 2012-2021 were analyzed, and minimum inhibitory concentrations were determined. β-lactamase-encoding genes were identified using multiplex polymerase chain reaction assays. The results showed that imipenem-resistant P. aeruginosa isolates had different susceptibility profiles and fewer carbapenemase genes compared to meropenem-resistant or doripenem-resistant isolates. Ceftazidime-avibactam and ceftolozane-tazobactam had higher susceptibility rates than meropenem-vaborbactam for meropenem-resistant P. aeruginosa. These findings are important for resistance trend monitoring and accurate antimicrobial treatment.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Laura Corbella, Jorge Boan, Rafael San-Juan, Mario Fernandez-Ruiz, Octavio Carretero, David Lora, Pilar Hernandez-Jimenez, Maria Ruiz-Ruigomez, Isabel Rodriguez-Goncer, Jose Tiago Silva, Francisco Lopez-Medrano, Manuel Lizasoain, Jennifer Villa, Jose Manuel Caro-Teller, Jose M. Aguado
Summary: Limited clinical experience suggests that ceftazidime-avibactam (CAZ-AVI) is a valid alternative for treating multidrug or extremely resistant Pseudomonas aeruginosa infections.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Infectious Diseases
Pattarachai Kiratisin, Krystyna Kazmierczak, Gregory G. Stone
Summary: In Africa/Middle East and Latin America, carbapenemase-producing Enterobacterales without MBL were not resistant to CZA; resistance rates were <= 4.5% in Europe and Asia/South Pacific. Enterobacterales in Latin America predominantly carried KPC carbapenemase, while in Africa/Middle East OXA-48-like carbapenemases were most frequently detected, and in Asia/South Pacific most isolates carried NDM carbapenemases.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Article
Microbiology
James A. Karlowsky, Sibylle H. Lob, C. Andrew DeRyke, David W. Hilbert, Michael T. Wong, Katherine Young, Fakhar Siddiqui, Mary R. Motyl, Daniel F. Sahm
Summary: The study evaluated the susceptibility of P. aeruginosa strains isolated from patients in the United States to C/T, IMR, and CZA. The results showed that most isolates were susceptible to C/T, and IMR demonstrated greater activity against C/T-nonsusceptible strains compared to CZA.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)